70-Year-Old Harvard Professor Took an Investment Gamble Which Made Him a Billionaire Overnight

70-Year-Old Harvard Professor Took an Investment Gamble Which Made Him a Billionaire Overnight

While the coronavirus recession has its fair share of losers in the stock market, there is a segment of companies and investors that hit it big because of the pandemic.

One of them is immunologist and Harvard Medical School professor Dr. Timothy Springer, Ph.D., who just proved that it’s never too late to join the billionaire’s club.

A Wise Investment

TRMK/Shutterstock: Originally called ModeRNA, the company initially focused on a method that modified mRNA

When Springer isn’t busy pioneering research in the field of medicine, he’s got his sights focused on investing in the biotechnology industry. His best bet to date is his stake in the Massachusetts-based drug development company, Moderna.

The professor, whose work has applications in treating autoimmune diseases, reportedly put $5 million in the company a couple of years ago. By 2018, Moderna went public and subsequently had the biggest biotech sector IPO in history.

Founded in 2010, Moderna was based on research by Derrick Rossi, a stem cell biologist at Harvard University. It was Rossi who approached his faculty colleague Springer to invest in his project. Springer agreed and became Moderna’s first investor.

Making His First Hundred Million

Harvard University: Springer has been teaching at the Harvard Medical School since 1977

It’s worth noting that Springer has enjoyed financial success way before Moderna came into the picture. He actually made his first $100 million in the late ‘90s after selling his personal venture LeukoSite to a large pharmaceutical company.

It was from this huge pay that the professor took the $5 million he funded Moderna with.And it looks like Springer spent the rest of his money wisely as he is also the founder of two other companies in the biotechnology sector: Scholar Rock and Morphic Therapeutic.

Unbelievable Returns

New Africa/Shutterstock: Moderna is the first to start human trials for a possible COVID-19 vaccine

Before the recent surge in Moderna’s stock, Springer already held $400 million worth of the company’s IPO. He is currently its fourth-largest shareholder.

Considering the coronavirus-caused push Moderna recently saw though, the professor’s stake went to give him a whopping 17,000% return on investment. And at the age of 72, Springer officially became a billionaire.

As Moderna continues to help find a vaccine for the ongoing pandemic, the United States government has reportedly funded the company $438 million to aid in its quest.

Its market cap currently stands at $10 billion. The feat is made even more impressive by the fact that, as of today, none of Moderna’s products have reached the final stages of a clinical trial or received a go signal from the Food and Drug Administration (FDA).

You May Also Like

Is It a Good Time to Invest in Bitcoin After Its Recent Rally? Biz & Finance

Is It a Good Time to Invest in Bitcoin After Its Recent Rally?

Bitcoin’s recent surge past $90,000 has reignited discussions about whether now is a good time to invest. Following years of volatility, Bitcoin has surpassed significant milestones, including breaching $70,000 earlier this year. As the cryptocurrency approaches the $100,000 mark, investors are increasingly curious about its potential as part of a diversified portfolio. However, Bitcoin’s unique […]

Ami Ciccone December 5, 2024
Read More →
Does a Reverse Mortgage Go Through Probate? Biz & Finance

Does a Reverse Mortgage Go Through Probate?

Reverse mortgages often spark curiosity and confusion, especially when it comes to their implications after a homeowner’s death. It’s understandable why many wonder if a reverse mortgage goes through probate, as this question arises from the complex nature of reverse mortgages and their unique impact on estate planning. Here’s a clear breakdown of what happens […]

Ami Ciccone September 13, 2024
Read More →
Can Suing A Company Affect Its Stock Price? Biz & Finance

Can Suing A Company Affect Its Stock Price?

When considering legal matters for a stock, it is essential to recognize the significant role that legal actions play in the financial markets. Legal disputes can introduce uncertainty, shift investor sentiment, and ultimately influence a company’s market value. Understanding these dynamics can help investors make more informed decisions. The immediate reaction to news of a […]

Ami Ciccone August 14, 2024
Read More →
How Does Inflation Affect Businesses? Biz & Finance

How Does Inflation Affect Businesses?

Retail business owners are often on the front lines when grappling with the ripple effects of inflation. From surging supplier prices to shifts in consumer spending habits, the complexities of inflation are felt acutely in the retail sector. The ongoing geopolitical tensions, such as those between Ukraine and Russia, compound these challenges, making the business […]

Ami Ciccone July 17, 2024
Read More →